Rhumbline Advisers Cuts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Rhumbline Advisers lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the third quarter, HoldingsChannel reports. The fund owned 168,001 shares of the biopharmaceutical company’s stock after selling 2,658 shares during the quarter. Rhumbline Advisers’ holdings in Regeneron Pharmaceuticals were worth $94,462,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of REGN. Krilogy Financial LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $1,176,000. ABC Arbitrage SA acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,108,000. Cove Private Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 8.7% during the 3rd quarter. Cove Private Wealth LLC now owns 500 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 40 shares during the period. Wealthfront Advisers LLC lifted its position in shares of Regeneron Pharmaceuticals by 28.7% during the 3rd quarter. Wealthfront Advisers LLC now owns 5,940 shares of the biopharmaceutical company’s stock valued at $3,340,000 after buying an additional 1,325 shares in the last quarter. Finally, AlTi Global Inc. grew its stake in Regeneron Pharmaceuticals by 11.8% in the 3rd quarter. AlTi Global Inc. now owns 464 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 49 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 3.2%

Shares of Regeneron Pharmaceuticals stock opened at $778.97 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock’s 50 day simple moving average is $759.25 and its 200-day simple moving average is $662.51. The stock has a market cap of $81.87 billion, a P/E ratio of 18.74, a P/E/G ratio of 2.03 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm earned $12.07 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.47%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent analyst reports. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Evercore boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Finally, Guggenheim increased their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,636 shares of company stock valued at $2,862,920. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.